Summary of New Wei Medical Conference Call Company Overview - New Wei Medical focuses on interventional brain-machine interface technology, utilizing a minimally invasive approach through the jugular vein to access brain vessels for signal collection, differentiating itself from invasive technologies like those developed by Musk's company [2][5] Key Points and Arguments - Product Development Timeline: New Wei Medical plans to complete type testing and animal experiments by mid-2026, initiate clinical enrollment in the second half of 2026, and expects to finish all patient enrollment and submit for regulatory approval by 2028 [2][3][4] - Independent Subsidiary: The company has established an independent subsidiary named "Wei Brain Technology" to focus on the development of interventional brain-machine interfaces and related investment collaborations, with plans to expand the team to 20 members [2][9] - Technical Specifications: The interventional brain-machine interface device uses a nickel-titanium alloy stent with electrode configurations of 4 or 16 channels, with signal processing chips placed subcutaneously beneath the clavicle [2][8] - Animal Testing Results: Animal experiments have shown stable signal strength, with a small-tailed sheep experiment maintaining 97%-98% signal strength after 18 months, validating the feasibility of the technology [2][11] Competitive Landscape - Comparison with Musk's Technology: New Wei Medical's approach avoids the need for craniotomy, which is required by Musk's invasive technology. This results in lower surgical risks and higher patient acceptance. The company claims its method ensures stable signal transmission due to the encapsulation of the electrode stent by the vessel wall, preventing displacement issues [5][10] Clinical Trial Plans - First Patient Enrollment: The company plans to conduct its first clinical trial in 2026, targeting 30-50 patients primarily for limb rehabilitation indications, with a follow-up period of approximately six months [4][10] - Regulatory Recognition: New Wei Medical is the only approved project for interventional technology routes in a national initiative co-hosted by the Ministry of Industry and Information Technology and the National Medical Products Administration, indicating recognition of its innovative technology [4][6] Challenges and Future Directions - Technical Limitations: The interventional approach may face challenges in accessing smaller, more distal blood vessels, necessitating the design of smaller electrode stents for broader brain area applications [11][12] - Future Applications: The company aims to extend its technology from motor function areas to visual and auditory functions, as well as explore emotional management and other research directions [11][12] Additional Insights - Market Potential: With 2,500 hospitals in China capable of performing the minimally invasive procedure, New Wei Medical is positioned to leverage a broad market for its technology [5] - Investment and Collaboration: The subsidiary aims to attract external partnerships and capital to enhance its operational capabilities and cover more consumer-level application scenarios [9]
心玮医疗20260108